Loading
A phase 1/2 trial of GNC-038 in non-Hodgkin lymphoma, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT05623982 by Sichuan Baili Pharmaceutical Co., Ltd., with 40 participants planned, started 2022-09-26 and due to reach its primary completion in 2026-12. Interventions recorded: GNC-038.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SystImmune / Sichuan Biokin, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares SystImmune / Sichuan Biokin, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Shares SystImmune / Sichuan Biokin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/